18F-Fluciclovine, PET/CT and MRI, and cfDNA in Differentiating Tumor Progression in Patients with Glioblastoma

Inclusion Criteria

• Initial diagnosis of glioblastoma (histologic or molecular proof)
• Completion of chemoradiation
• New contrast-enhancing lesions or lesions showing increased enhancement (> 25% increase) on standard MRI after completion of chemoradiation
• Recommended for clinical surgical resection
• Life expectancy of greater than 3 months in the opinion of an investigator or treating physician
• Karnofsky performance status >= 60
• Participants must be informed of the investigational nature of this study and be willing to provide written informed consent and participate in this study in accordance with institutional and federal guidelines prior to study-specific procedures

Exclusion Criteria

• Inability to tolerate imaging procedures in the opinion of an investigator or treating physician
• Females who are pregnant or breast feeding at the time of screening will not be eligible for this study; a urine pregnancy test will be performed in women of child-bearing potential at screening
• Any current medical condition, illness, or disorder as assessed by medical record review and/or self-reported that is considered by a physician investigator to be a condition that could compromise participant safety or successful participation in the study
• Contraindications to MRI or use of gadolinium contrast